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Abstract
Background: Pregnancy in women with advanced CKD becoming increasingly common. However, experience with
low-protein diets in CKD patients in pregnancy is still limited.
Aim of this study is to review the results obtained over the last 15 years with moderately restricted low-protein
diets in pregnant CKD women (combining: CKD stages 3-5, proteinuria: nephrotic at any time, or > =1 g/24 at start
or referral; nephrotic in previous pregnancy). CKD patients on unrestricted diets were employed for comparison.
Methods: Study period: January, 2000 to September, 2015: 36 on-diet pregnancies (31 singleton deliveries, 3 twin
deliveries, 1 pregnancy termination, 1 miscarriage); 47 controls (42 singleton deliveries, 5 miscarriages). The diet is
basically vegan; since occasional milk and yoghurt are allowed, we defined it vegan-vegetarian; protein intake
(0.6–0.8 g/Kg/day), keto-acid supplementation, protein-unrestricted meals (1–3/week) are prescribed according to
CKD stage and nutritional status. Statistical analysis was performed as implemented on SPSS.
Results: Patients and controls were similar (p: ns) at baseline with regard to age (33 vs 33.5), referral week (7 vs 9),
kidney function (CKD 3-5: 48.4 % vs 64.3 %); prevalence of hypertension (51.6 % vs 40.5 %) and proteinuria >3 g/
24 h (16.1 % vs 12.2 %). There were more diabetic nephropathies in on-diet patients (on diet: 31.0 % vs controls 5.
3 %; p 0.007 (Fisher)) while lupus nephropathies were non-significantly higher in controls (on diet: 10.3 % vs
controls 23.7 %; p 0.28 (Fisher)). The incidence of preterm delivery was similar (<37 weeks: on-diet singletons 77.
4 %; controls: 71.4 %). The incidence of other adverse pregnancy related outcomes was non-significantly lower in
on-diet patients (early preterm delivery: on diet: 32.3 % vs controls 35.7 %; birth-weight = <1.500 g: on diet: 9.7 % vs
controls 23.8 %). None of the singletons in the on-diet series died, while two perinatal deaths occurred among the
controls (p = 0.505).
The incidence of small for gestational age (SGA <10th centile) and/or extremely preterm babies (<28th week) was
significantly lower in singletons from on-diet mothers than in controls (on diet: 12.9 % vs controls: 33.3 %; p: 0.04
(Fisher)).
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Conclusion: Moderate protein restriction in the context of a vegan-vegetarian supplemented diet is confirmed as a
safe option in the management of pregnant CKD patients.
Keywords: Low-protein diets, Supplemented diets, Pregnancy, CKD, Maternal-foetal outcomes, Small for gestational
age baby, Preterm delivery
Background
When we prescribed a low-protein diet to the first preg-
nant patient with severe proteinuria and diabetic ne-
phropathy (a case which gave us the opportunity to start
a “joint venture” between Nephrology and Obstetrics),
we did not foresee that fifteen years later our Unit would
have followed-up a few hundred pregnancies, about 5 %
of which involved subjects on a protein-restricted diet
[1–5]. We also did not foresee that several large studies
would have challenged the “meat eaters” in favour of
Mediterranean or vegetable-based diets, thus leading to
reconsider the role of protein intake in the overall popu-
lation, as well as in CKD [6–14]. We were mainly wor-
ried about the patient’s increasing levels of proteinuria,
and we did not know what else we could do besides
keeping blood pressure under control, ordering bed rest
(still a widely used procedure) and checking the baby’s
growth curve [1].
On the basis of the available data on hyper-filtration in
CKD and on the effect of low-protein diets in reducing
the “work load” on the remnant nephrons, we chose to
start her on the diet that we considered the “best” one
available in our hands, i.e. a low-protein, vegan, supple-
mented diet [15–18].
After our patient delivered a healthy male baby, ad-
equate for gestational age, at the 30th gestational week,
we started prescribing a low-protein, vegan-vegetarian
diet, with a simplified qualitative schema, to other preg-
nant patients with severe kidney function impairment or
relevant proteinuria [1]. Our first results, involving 12
pregnancies, were promising enough to double the num-
ber of patients in a few years [2, 4]. The subsequent ana-
lysis on 22 live-born singleton deliveries showed the
almost paradoxical finding of better growth in children
delivered by on-diet mothers as compared to children of
CKD mothers on an unrestricted diet [4].
At the time of our first experiences, 1–1.2 g of pro-
teins /Kg day was considered the “normal” protein in-
take, and the intake in pregnant women was often
higher, thus making our diets conflicting with the com-
mon beliefs in pregnancy. However, interest in vegan-
vegetarian diets grew over the following years, and they
are now considered safe in all phases of life, including
pregnancy and lactation, provided that vitamins and mi-
croelements were controlled and integrated when
needed [19–31].
Meanwhile, we gradually integrated the recommenda-
tion that patients should avoid both excessive weight
gain; this was carried out by shifting from a purely quali-
tative diet prescription to the present qualitative-
quantitative one [2, 4] (Appendix).
The main drawback of our previous studies was the dif-
ficulty of recruiting a homogeneous control group [2, 4].
Thus, the novelty of the present analysis, which is aimed
at reviewing the results gathered over 15 years, is that the
results of on-diet pregnancies are compared to a compos-
ite larger control group of pregnancies with similar clinical
characteristics.
Methods
Definitions and control policies
CKD was defined and staged according to K-DOQI guide-
lines, whenever possible according to pre-conceptional
data. Throughout pregnancy, GFR and proteinuria were
assessed by 24-h urine collections, as specified more in
detail elsewhere [5].
A newborn was defined as Small for Gestational Age
(SGA) when birth weight was below the 5th or below
the 10th centile, according to the birth weight references
that were used [32–34]. Due to the specific interest in
this point, we employed both the older Italian Parazzini
charts and the newer INeS (Italian Neonatal Study)
charts, and analysed the two cut-points at the 5th and
10th percentile [33, 34]. Preterm delivery, early preterm
delivery and extremely preterm delivery were defined as
before 37, 34 and 28 completed weeks of gestational age,
respectively [32].
Hypertension was defined as per the current guide-
lines; the antihypertensive treatment was mainly based
upon a combination of alphamethyl-dopa and nifedi-
pine, adding doxazosine, small doses of diuretics or
clonidine only when absolutely needed. Treatment
was adjusted at every clinical visit with a target of
120–130/60–70 mmHg [5].
The study was performed in two Italian settings:
Torino and Cagliari. These are the two Centers with the
greatest experience of management of CKD in preg-
nancy in Italy, that keep a conjoint database (TOCOS:
Torino Cagliari Observational Study [5]). For the sake of
this study, the cases were recruited in Torino, the con-
trols were selected in both settings, as further specified.
In both settings of care, the frequency of nephrological
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and obstetric visits, of blood and urine tests and of bio-
metric and Doppler studies of uterine and umbilical
arteries are tailored to the individual patient (visits:
1 week–1 month, biometry every 2–3 weeks in case of
SGA babies or at risk for foetal growth restriction;
Doppler assessment two-three times weekly in case of
Doppler anomalies), in keeping with the Italian best
practices in pregnant CKD patients [35, 36].
The low-protein diet
The low protein diet consisted in an adaptation of the
low-protein vegan diet employed in our centre, itself a
simplification of the original scheme by Barsotti and
Giovannetti [17, 18].
Unlike the Barsotti and Giovannetti diets, our basic
schemas are simplified: the food is chosen according to a
qualitative approach (allowed-forbidden), not weighed,
with a protein intake of 0.6 g/Kg/day (ideal weight), and
1–3 free meals per week. To allow the patient to follow
a vegan diet without the need to use legumes and cereals
in each meal, we added a supplementation of alpha-keto
analogues and aminoacids (Alpha-Kappa or Ketosteril
according to the availability over time): 1 pill/10 Kg of
ideal body weight [37, 38].
In an empirical attempt to balance the potential
advantages of low-protein diets in CKD and the habit of
increasing protein intake in pregnancy, we initially ad-
justed the diet from 0.6 to 0.6–0.8 g/Kg/day of proteins,
based on pre-conception weight, usually by increasing
the protein intake from the first (0.6 g/Kg/day) to the
last trimester (0.8 g/Kg/day). We also increased the
amino and keto-acids supplementation from 1 pill each
10 Kg to 1 pill each 8 Kg, and in patients with low body
weight, even up to 1 pill each 5 Kg in late pregnancy.
At the time of the first case, no report on these issues
had been found or made available by the company; no
report on safety concerns was available at that time or
was found at the subsequent updates.
Since patients often missed milk and yoghurt in their
diets, we allowed small quantities (100–150 mL per day)
in selected cases, and changed the definition of “vegan”
into “vegan-vegetarian”. On the basis of the functional
status, of the proteinuria levels and of the patients’ needs
and preferences, in keeping with the policy applied to
non-pregnant patients, we allowed 1–3 unrestricted
meals per week (without protein restriction but limited
in unsaturated fats and short-chain sugars).
On the account of the lack of indications on salt
restriction in pregnancy, we did not restrict salt; since
salt intake cannot be controlled by the analysis of the
24 h excretion in pregnancy, due to the lack of referral
standards, we limited our interventions to diet counsel-
ling in the cases with severe oedema or uncontrolled
hypertension.
In addition to the biochemical tests (targeted at CKD),
we progressively added iron status, B12, and 25-OH vita-
min D to the routine monthly tests; vitamins and iron
supplements were employed on the basis of the bio-
chemical results. Erythropoietin was used when needed,
with a haemoglobin target of 10 g/dL on account of the
physiological haemodilution of pregnancy.
The most recent version of the diet is reported in the
Appendix.
Indications for the diet and selection of controls
The main indications for the low-protein vegan-
vegetarian diets in pregnancy were progressively broad-
ened from the initial subjects with CKD stages 4-5 and/
or nephrotic syndrome to include pregnancy in patients
already on a supplemented vegetarian diet; CKD stages
3b or 3 with a progression trend before or during preg-
nancy; proteinuria above 3 g/day at any time of preg-
nancy, or proteinuria above 1 g/day at referral or in the
first trimester, previous nephrotic syndrome, increase or
development of proteinuria without any sign of pre-
eclampsia, or a combination of any of these elements.
The controls were selected according to the same cri-
teria from the Torino and Cagliari cohort. While the ne-
phrologists’ approach was very similar, in keeping with
our well-established cooperation, the Torino and Cagliari
Units differed with regard to the Obstetric policy to-
wards caesarean sections (more frequently performed in
Cagliari [5]), therefore this outcome was not considered
in the present study.
Statistical analysis
Descriptive analysis was performed as appropriate
(mean and standard deviation for parametric and
median and range for non-parametric data). Paired T-
test, Chi-square test, Fisher’s test, Mid-p test, and
Wilcoxon’s test were used for comparisons between
patients and controls and to evaluate the differences
from referral to delivery in patients and controls.
Significance was set at <0.05.
Statistical evaluation was performed using SPSS
vers18.0 for Windows (SPSS Chicago Ill, USA).
Ethical issues
Systematic counselling about the diet was provided.
Patients were informed that few data on the supple-
mented diet during pregnancy were available outside of
our group, furthermore, the limits and goals of the low-
protein diets were extensively discussed. The importance
of timely reporting of side effects or doubts was under-
lined; a written schema, progressively updated, was sup-
plied. The first version is available elsewhere [5]. The
most recent update is available in the Appendix.
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The study was approved by the Ethics committee of
the OIRM Sant’Anna (n° pratica 335; n° protocollo
11551/c28.2 del 4/3/2011). All patients signed a dedicate
informed consent.
Results
Baseline data
The main baseline data of the 36 patients who followed
the diet for at least one month and of the 31 patients
who delivered a live-born singleton baby (excluded: 3
twin deliveries, 1 pregnancy termination following the
mother’s wishes, 1 spontaneous miscarriage) are re-
ported in Table 1. Two patients in the on-diet group
undertook two pregnancies.
Table 2 reports the baseline data in the control group
of 47 pregnancies homogeneously selected according in
Torino and Cagliari; there were 42 singleton deliveries
and 5 spontaneous miscarriages.
The two groups are homogeneous with regard to the
main clinical parameters: age (singletons only: on diet:
33 vs controls 33.5 years); and referral week (7 vs
9 weeks). CKD stage was non significantly lower in on
diet patients (CKD 3-5: 48.4 % vs 64.3 %, p: 0.26), con-
versely, prevalence of hypertension was non significantly
higher (51.6 % vs 40.5 %, p: 0.48). Nephrotic range pro-
teinuria (16.1 % vs 12.2 %, p 0.74) was also non signifi-
cantly higher in on diet patients. The combination of
hypertension and proteinuria was present in 14/36
(38.9 %) on-diet patients and in 14/47 (29.8 %) controls
(p = 0.35). There were more diabetic nephropathies in on-
diet patients (on diet: 31 % vs controls: 5.3 %; p: 0.007)
while lupus nephropathies were non-significantly higher
in controls (on diet: 10.3 % vs controls 23.7 %; p: 0.28
(Fisher)), presumably as a reflection of the referral pattern
of the individual Nephrology Units.
Pregnancy outcomes: kidney function and proteinuria
All of the patients on the diet followed it throughout
pregnancy; no diet- or supplement- related side effects
were reported and abdominal discomfort, when present,
was not considered related to the diet itself. According
to dietary recall, compliance was good; however, espe-
cially in the second period, in which the diet was more
detailed and no more merely qualitative, some patients
complained that it was very intrusive in their daily life.
An increase in serum creatinine leading to a shift
towards a higher CKD stage was observed in 19.4 % on-
diet and 9.5 % controls (p: 0.2 (Fisher)).
Proteinuria increased significantly in both patients and
controls (new onset or doubling of proteinuria: 54.8 % of
on-diet subjects and 50 % of controls; p: 0.5 (Fisher)).
However, serum albumin and total proteins only moder-
ately, and non significantly decreased at the end of preg-
nancy (diet group: total proteins: 6.5 g/dL at start vs
5.7 g/dL at delivery, albumin 3.75 g/dL at start vs 2.9 g/
dL at delivery; control group: total proteins: 6.5 vs 6.1 g/
dL, albumin 3.4 vs 3.24 g/dL) (Tables 3 and 4).
At 3 months after delivery serum creatinine increased
and GFR decreased in both groups, in keeping with the re-
versal of pregnancy-related hyperfiltration. The decrease
in proteinuria is probably due both to the reversal of the
hyperflitraton phase, but other less known pregnancy-
related permeability changes mechanisms may also play a
role (Tables 3 and 4), Figs. 1, 2 and 3.
Pregnancy outcomes: prevalence of small for gestational
age and preterm babies
Tables 5 and 6 report the main data regarding birth-
weight and timing of delivery in on-diet patients and in
controls. No significant differences were observed for the
overall prevalence of preterm delivery (<37 completed ges-
tational weeks), which was over 70 % in both groups (on-
diet singletons 77.4 %; controls 71.4 %; p: 0.76), or in the
prevalence of children with birth-weight at or below 2.5
Kg (21/31: 66.7 % vs 25/42: 59.5 %, p: 0.32).
The Figs. 4 and 5, based upon the original Parazzini
charts that were the most commonly used references in
Italy throughout the study period, summarize the rela-
tionship between birth-weight and prematurity in the
two settings. Early preterm delivery (on diet: 32.3 % vs
controls: 35.7 %) and extremely low birth-weight (on
diet: 9.7 % vs controls: 23.8 %) were more common in
control groups, and the only two extremely preterm
deliveries were observed in the control group (p: 0.505).
The birth-weighty centiles, assessed by the Parazzini
chart, reference in most of the period of study, showed a
lower prevalence of babies below the 10th centile or
extremely preterm (below 28 weeks) in on diet patients
versus in controls; the difference (one tailed Fisher
exact test) reaches statistical significance (12.9 % vs
33.3 % p: 0.04). If centiles are calculated with INeS
charts, the figures are similar (below 10th centile:
9.7 % on diet vs 26.2 % controls, but the difference
doesn’t reach statistical significance (p: 0.068)).
Conversely, gestational age and birth weight did not
differ in the two cohorts (Tables 5 and 6 and Figs. 1 and
2). One twin child diet of on-diet mother died (cerebral
haemorrhage after heart surgery for cardiac malforma-
tion); none of the singletons died in the on-diet series,
while two perinatal deaths occurred in the control group
(p = 0.505).
Discussion
An often-cited quote by Feuerbach states: “a man is
what he eats”; indeed there are good reasons to reflect
on Feuerbach’s clever and polemic sentence in the era of
epigenetics and of rediscovery of the importance of what
we eat to prevent diseases and possibly to cure them.
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Table 1 Baseline data: “On-diet”: 36 pregnancies in patients who followed a supplemented vegan diet in pregnancy
(31 singleton deliveries)
Case Age
(yrs)
Pre-conceptional;
Referral-week
Kidney disease sCr mg/dL (EPI-GFR
mL/min)
CKD
stage
PtU
(g/24 h)
Pt/Alb
(g/dL)
HT Therapy
at referral
BMI
1 35 pre; ICSI Diab neph 1.2 (59) 3 2.5 5.9/2.8 Yes Insulin, doxazosine 23.5
2 35 pre; 8w Diab neph 1.6 (45) 4 1.8 6.5/3.8 No Insulin 22
3 28 7w Sponge kidney 3.2 (19) 4 0.8 6.5/3.5 No EPO, Vit. D 22
4 37 pre; 6w Diab neph 1.2 (58) 3 5.9 5.8/3.2 No Insulin 22
5 32 6w SLE 0.7 (115) 1 2.7 6.0/3.1 Yes Pred., ASA, omeprazole, a-MD 24
6 35 pre; 7w Reflux 3.2 (18) 4 1.0 8.4/4.5 Yes Vit. D, b-blocker ASA 19
7 29 9w Diab neph 1.5 (47) 3 6.3 6.6/3.6 Yes Insulin, nifedipine 20
8 38 17w fibrillary GN 0.6 (116) 1 3.6 5.8/2.6 No None 22
9 32 6w Kidney graft 1.2 (60) 2 0.5 6.9/4.0 No Pred., CyA, ranitidine, ASA, 24
10 20 5w SLE 0.6 (132) 1 2.5 6.8/3.3 No Pred. 21
11 37 7w Kidney graft 1.5 (44) 3 0.8 7.0/3.9 Yes Pred., CyA, VitD, nifedipine, ASA EPO,
ranitidine
27
12 30 6w IgA GN 1.3 (55) 3 0.7 6.9/4.1 No Levothyroxine 18.9
13 28 10w IgA GN 1 (77) 2 2 6.6/3.7 No None 19.9
14 36 pre; 5w Diab neph 1 (68) 2 0.6 6.4/4.1 Yes Lansoprazole, levothyroxine, ASA,
Niphedipine, insulin,
21.5
15 35 7w Diab neph 1.2 (56) 3 0.7 7.4/4.3 No Insulin 18.2
16 40 24w Diab neph 0.9 (76) 2 3.1 6.7/3.3 Yes Insulin, levothyroxine, Nifedipine 24
17 36 20w IgA GN 1.1 (64) 2 2.4 5.6/4.1 No None 22.3
18 36 pre; 7w SLE 2.9 (20) 4 3.4 6.5/3.9 Yes Pred., levothyroxine, a-MD 24.5
19 38 6w FSGS 0.6 (116) 1 2.1 6.3/3.3 No CyA 25
20 33 pre; 8w Kidney graft 1.3 (52) 3 0.2 7.2/3.9 Yes Pred, TAC 30
21 31 pre; 9w Sponge kidney 1.6 (43.3) 3 0.3 6.5/4.0 Yes ASA, a-MD 23.4
22 33 pre; 7w Reflux 0.7 (110.4) 1 0.8 6.0/3.7 Yes ASA, b-bloc 21.8
23 38 pre; 6w Pyelonephritis 1.2 (59) 3 0.2 6.5/3.9 Yes a-MD 19.7
24 26 5w Single kidney,
previous HUS
1 (78) 2 0.3 6.8/3.8 Yes ASA 23.4
25 41 pre; 7w GN 0.8 (86.6) 2 0.8 7.2/3.8 Yes ASA 33.6
26 32 6w IgA GN 1 (74.7) 2 0.6 6.8 /3.9 No ASA 24.9
27 36 18w Diab neph 0.7 (106.3) 1 0.9 7.4/4.4 Yes ASA, a-MD, Insulin 34
28 33 27w LLAC 0.4 (136.2) 1 1.3 6.0/3.6 Yes a-MD 29.7
29 33 14w Unknown 0.8 (105.6) 1 2.2 5.7/3.0 No ASA 24.8
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Table 1 Baseline data: “On-diet”: 36 pregnancies in patients who followed a supplemented vegan diet in pregnancy
(31 singleton deliveries) (Continued)
30 32 30w Unknown 1.7 (39.6) 3 0.1 6.2/3.6 No / 26.7
31 31 8 w Diab neph 1.48 (47) 3 0.1 6.78/4.68 No ASA, Insulin 19.5
32 (twin) 31 21w Diab neph 0.5 (128) 1 5.4 5.5/2.8 No Insulin, levothyroxine 17.9
33 (twin) 37 12w Unknown 0.7 (112) 1 0.8 7.1/3.5 No None 31.4
34 (twin) 39 11 w Previous PNA 0.57 (184.1) 1 0.29 6.11/3.37 No ASA 32.32
35 (termination) 26 18w MGN 0.6 (126) 1 5.5 5.1/2.3 No None 19
36 (miscarriage) 37 7w Kidney graft 1.7 (38) 3 0.1 6.9/3.9 Yes Pred., TAC, EPO, ASA,
omeprazole, Doxazosin,
b-bloc
25.1
Summary data all
cases
Median (min-max)
34
(20–41)
7 (5–30) _ sCr
1.05 (0.4–3.2)
GFR-EPI
66.0 (18.0–184.1)
2 (1–4) 0.8
(0.1–6.3)
Pt
6.5
(5.1–8.4)
Alb
3.75
(2.3–4.68)
17/36
47.2 %
_ 23.4
(17.9–34.0)
Summary data
Singletons
Median (min-max)
33
(20–41)
7 (5–30) _ sCr
1.20 (0.4–3.2)
GFR-EPI
60.0 (18.0–136.2)
3 (1–4) 0.9
(0.1–6.3)
Pt
6.5
(5.6–8.4)
Alb
3.8
(2.6–4.68)
16/31
51.6 %
_ 23.4
(18.2–34.0)
Data at referral: data observed at the first follow-up in our unit
HT hypertension, SLE systemic lupus erythematosus, IgA GN IgA nephropathy, FSGS focal segmental glomerlosclerosis, Diab Neph diabetic nephropathy, BMI body mass index, PtU 24 hour proteinuria, sCr serum
creatinine, GFR glomerular filtration rate, SLE systemic lupus erythematosus. CyA cyclosporine A, ASA acetyl salicylic acid, Pred. prednisone, TAC tacrolimus, EPO erythropoietin, B-Bloc beta blocker, a-MD alpha
methyldopa, ICSI intracytoplasmatic sperm injection
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Table 2 Baseline data: “controls”: 47 pregnant patients on unrestricted diet in pregnancy (22 singleton deliveries in Cagliari, 20 in Torino)
Case Age (yrs) Pre-conceptional;
Referral-week
Kidney disease sCr mg/dL (EPI-GFR
mL/min)
CKD
stage
PtU
(g/24 h)
Pt/Alb
(g/dL)
HT Therapy at referral BMI
1 33 11w IgA GN 0.9 (84.3) 2 1.1 6.0/2.9 No Pred 20.2
2 34 pre; 7w SLE 0.7 (113.4) 1 1.3 5.8/3.5 No Steroids, AZA 19.6
3 34 pre; 6w SLE 0.7 (113.4) 1 1.3 6.3/2.9 Yes a-MD, Pred., CyA 20.8
4 38 pre; 22w Unknown 0.8 (93.8) 1 1.7 Na Yes ASA, Nifedipine, a-MD 26
5 29 pre; 5w IgA GN 0.9 (86.7) 2 2.1 6.3/3.5 Yes a-MD 22.1
6 26 pre; 8w Diab neph 0.4 (144.2) 1 2.6 5.6/3.3 No ASA, Insulin 23.4
7 35 pre; 7w SLE, LLAC 0.5 (129.3) 1 3.9 5.2 /2.9 No Pred 20.2
8 19 pre; 13w SLE 0.6 (135.6) 1 4 5.9/3 No none 18.8
9 36 pre; 13w FSGS 0.9 (82.5) 2 4.2 5.7/3.1 Yes ASA, a-MD 20.3
10 41 pre; 6w SLE 1 (71.9) 2 5.4 5.5/3.6 Yes a-MD 18.3
11 35 pre; 20w Diab neph 1.2 (58.7) 3 0.1 Na Yes a-MD, Insulin 25.6
12 39 pre; 7w SLE 1.4 (47.4) 3 0.3 6.5/3.7 Yes Pred., AZA 23
13 32 pre; 9w SLE 1.4 (49.8) 3 0.8 6.7/4.5 Yes Pred 21.6
14 35 pre; 8w IgA GN 1.4 (50) 3 1.7 6.8/3.3 No none 24.8
15 38 pre; 7w Unknown 1.6 (40.6) 3 1.4 6.2/4.3 No none 23.9
16 31 6w IgA GN 1.6 (42.6) 3 ++ 7/3.3 No none 32.5
17 36 pre; 6w GN 1.8 (35.7) 3 0.4 7.3/ 4 No none 22.5
18 23 pre; 13w Unknown 1.9 (36.6) 3 2.8 6.1/ 3 No none 30.1
19 30 na IgA GN 1.4 (50) 3 6.2 na Yes a-MD 21.6
20 34 pre; 12w SLE, LLAC 2.2 (28.4) 4 1.2 5.7/3.2 Yes a-MD, ASA, EPO 21.4
21 28 7w Unknown 1.6 (43.9) 3 1.6 7.4/ 4.3 No none 23.7
22 33 pre; 12w GN 0.5 (127.6) 1 1.1 7/4 No none 21.8
Summary data
Cagliari
34
(19–41)
8 (5–22) sCr
1.1 (0.4–2.2)
GFR-EPI
65.3 (28.4–144.2)
1.6
(0.1–6.2)
Pt
6.2
(5.2–7.4)
Alb
3.3
(2.9–4.5)
10
45.5 %
21.95
(18.3–32.5)
1 39 Pre; 8 w Interstitial 1.6 (40) 3 1.3 7.3 /3.7 Yes Felodipine, Doxazosin,
Levotiroxina, ASA
26.7
2 27 14 w Reflux 1.5 (47) 3 0.3 6.5/3.4 No None 18.0
3 34 20 w Chronic PN 1.5 (45) 3 2.0 Na No None 23.3
4 23 13 w IgA GN 1.3 (56) 3 0.5 6.4/3.1 Yes a-MD, ASA 22.7
5 32 Pre; 5 w IgA GN 1.2 (58) 3 0.3 6.1/3.4 No Steroids, Allopurinole 19.1
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Table 2 Baseline data: “controls”: 47 pregnant patients on unrestricted diet in pregnancy (22 singleton deliveries in Cagliari, 20 in Torino) (Continued)
6 35 Pre; 8 w IgA GN 1.3 (54) 3 0.5 6.6/2.7 Yes a-MP, Niphedipine 24.4
7 22 27 w Reflux 2.9 (22) 4 0.5 7.3/3.4 No Niphedipine 22.2
8 39 Pre; 14 w Chronic PN 1.4 (47) 3 0.2 8.1/4.0 Yes B-bloc, ASA 18.4
9 31 20 w Reflux 1.3 (54) 3 0.6 7.2/3.7 Yes B-bloc, Doxazosine, Niphedipine,
Isosorbide
19.5
10 25 33 w Reflux 1.3 (57) 3 0.8 6.0/3.1 Yes a-MP 19.3
11 35 7; w Interstitial 1.3 (52) 3 0.6 6.0/3.2 Yes None 25.6
12 33 Pre; 12w Chronic PN 1.2 (60) 3 0.1 6.4/3.2 No Clonidine, a-MP, ASA 19.7
13 30 6 w Kidney graft 1.2 (59) 3 0.2 7.6/3.2 No TAC, Pred, Pantoprazole,
Allopurinolo
20.3
14 32 29 w HIV neph. 1.43 (56) 3 0.4 7.0/3.1 No Antiretroviral therapy Omeprazole 20.0
15 36 6 w Kidney graft 1.1 (56) 3 0.1 6.9/4.7 No Pred, CyA, Omeprazole, ASA 24.7
16 38 Pre; 8 w single kidney 0.8 (56) 3 0.1 6.8/4.4 No Calcium carbonate 15.6
17 27 5 w SLE 0.6 (193.6) 1 1.45 7.09/4.37 No ASA, Steroids 30.4
18 37 20 w FSGS 0.7 (81.6) 2 2.33 6.56/3.62 No none 23.6
19 26 12 w IR e proteinuria 1.1 (101.2) 1 2 6.45/3.49 No ASA 32.4
20 36 16 w PNC 0.6 (122) 1 1.03 7.55/4.10 No Thyroxine 20.2
21 (miscarriage) 38 7 w Chronic PN, single
kidney
1.9 (31) 3 0.1 7.3/5.0 No None 24.9)
22 (miscarriage) 37 Pre; 8 w Single kidney 0.8 (58) 3 0.1 7.6/4.7 No None 15.6
23 (miscarriage) 36 5 w Kidney graft 1.3 (53) 3 0.4 Na No CyA, AZA 25.5
24 (miscarriage) 37 Pre; 5 w single kidney 0.9 (55) 3 0.1 na No Calcium carbonate, 16.2
25 (miscarriage) 30 9 w Diab. Neph 1.4 (50) 3 0.2 6.9/4.1 No Insuline 22.7
Summary data Torino 34
(22–39)
9 (5–33) _ sCr
1.3 (0.6–2.9)
GFR-EPI
56.0 (22.0–193.6)
3 (1–4) 0.4
(0.1–
2.33)
Pt
6.9
(6.0–8.1)
Alb
3.55
(2.7–5.0)
7
28.0 %
_ 22.2
(15.6–32.4)
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Table 2 Baseline data: “controls”: 47 pregnant patients on unrestricted diet in pregnancy (22 singleton deliveries in Cagliari, 20 in Torino) (Continued)
Summary data all
controls:
42 singleton
33.5
(19–41)
9 (5–33) _ sCr
1.25 (0.4–2.9)
GFR-EPI
56.0 (22.0–193.6)
3 (1–4) 1.1
(0.1–6.2)
Pt
6.5
(5.2–8.1)
Alb
3.4
(2.7–4.7)
17
40.5 %
_ 21.95
(15.6–32.5)
P cases vs controls
(singletons)
0.443 0.154 _ sCr
0.716
GFR-EPI
0.680
0.139
Chi 2
0.585 Pt
0.952
Alb
0.073
0.479
(Chi2)
_ 0.237
Data at referral: data observed at the first follow-up in our unit
HT hypertension, SLE systemic lupus erythematosus, IgA GN IgA nephropathy, FSGS focal segmental glomerlosclerosis, Diab Neph diabetic nephropathy, BMI body mass index, PtU 24 hour proteinuria, sCr serum
creatinine, GFR glomerular filtration rate, SLE systemic lupus (erithematosus)elim erythematosus. CyA cyclosporine A, ASA acetyl salicylic acid, Pred. prednisone, TAC tacrolimus, EPO erythropoietin, B-Bloc beta blocker, a-
MD alpha methyldopa
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Table 3 Maternal data at delivery: “on-diet”: 31 singleton deliveries and 3 twin deliveries
Case sCr mg/dL (EPI-GFR mL/min) Stage CKD PtU g/24 h Pt/Alb (g/dL) Weight gain Hospitalization sCr mg/dL
(EPI-GFR mL/min) 3 months
PtU g/die
Serum Alb g/dl
3 months
1 1.8 (36) 3 6.2 4.8/1.9 9 (13.4 %) 95 2.0 (45) 3/2.5
2 1.8 (36) 3 5.6 5.7/2.8 11 (20 %) 73 1.9 (40) 4/3
3 3.7 (16) 4 2.6 6.3/3.6 9 (16 %) 55 4.5 0.3/3.6
4 2 (31) 3 1.9 5.6/2.9 9 (18 %) 47 2.1 (21) 1.5/3.1
5 0.7 (115) 1 3.4 4.8/2.9 14 (21.5 %) 123 - -
6 2.9 (20) 4 2.0 6.2/2.9 10 (21.7 %) 80 2.8 (25) 1.5/3.5
7 5 (11) 5 17.3 4.2/1.8 16 (25 %) 93 4.3 (19) 5/3.1
8 0.6 (116) 1 2.1 5.0/2.4 10 (20 %) 30 0.8 (120) 4/3.2
9 1.3 (54) 3 3.6 5.3/2.8 8 (12 %) 84 1.2 (64) 1.3/-
10 0.5 (140) 1 2.9 5.4/2.7 11 (17 %) 63 0.7 (125.1) 6.2/2.8
11 1.8 (35) 3 5.4 5.4/2.8 5 (7 %) 99 1.7 (52.9) 6.8/3.8
12 0.8 (99) 1 5.7 5.5/2.7 10 (17.9 %) 9 1.2 (60.6) 5.7/3.2
13 1.5 (45) 3 5.5 5.0/2.6 4 (7.8 %) 28 2.9 (23.3) 3.4/4
14 1 (73) 2 4.7 4.5/2.2 12 (21 %) 29 0.9 (82.5) 4.4/2.2
15 1.5 (44) 3 9.4 5.5/2.6 8 (14 %) 24 1.9 (33.7) 1.3/5.7
16 1 (72) 2 4.4 6.4/2.8 14 (30.4 %%) 24 0.9 (80.2) 1.4/3.5
17 1.1 (65) 2 2.2 6.0/2.9 11 (20.4 %) 9 na na
18 3.6 (15) 4 3.4 5.8/3.2 12 (17.9 %) 26 3.1 (18.5) 1.3/3.2
19 0.6 (115) 1 1.4 5.2/2.6 10 (14.1 %) 16 0.7 (110.3) 2.5/2.7
20 1.8 (37) 3 0.8 6.7/3.3 7 (9.2 %) 12 1.7 (39.1) 1/3.9
21 1.2 (60) 2 1.7 5.9/3.1 15 (23.8 %) 8 1.8 (37.2) 0.3/4.1
22 0.7 (105) 1 0.9 5.7/2.9 10 (20.4 %) 3 0.8 (98.7) 0.8/4.5
23 1 (69) 2 0.3 6.8/3.6 12 (22.6 %) 4 1.3 (53.7) 0.1/3.7
24 1.2 (63.2) 2 0.6 6.7/3.6 6 (10 %) 13 1.1 (69.5) 0.1/4
25 0.8 (90.5) 1 1.8 5.5/3.2 6 (7 %) 7 0.9 (76.6) 0.7/4.3
26 1 (75.6) 2 0.8 6.6/3.1 22 (31 %) 5 1.0 (74.7) 0.8/3.3
27 0.9 (86) 2 0.9 5.9/3.1 1 (1 %) 16 na na
28 0.5 (131.1) 1 0.4 6.0/2.7 −2 (−2.5 %) 5 0.6 (118.9) 0.5/4.7
29 1 (89.9) 2 6.2 5.5/2.9 6 (7.9 %) 5 1.0 na
30 2 (31.6) 3 0.1 6.4/3.2 9 (15 %) 22 na na
31 2.33 (27) 4 0.41 6.4/3.3 15 (22 %) 24 na na
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Table 3 Maternal data at delivery: “on-diet”: 31 singleton deliveries and 3 twin deliveries (Continued)
32 (twin) 0.7 (117) 1 11.8 4.1/1.8 21 (42 %) 76 0.6 (121.8) 1.5/3.7
33 (twin) 0.9 (81.4) 2 na 6.1/3.3 3 (3.3 %) 8 na na
34 (twin) 0.6 (120) 1 0.9 5.6/3.0 24 (27.3 %) 14 na na
Summary data (singletons) sCr
1.2 (0.5–5.0)
GFR-EPI
63.2 (11.0–140.0)
3 (1–4) 2.2 (0.1–17.3) Pt
5.7 (4.2–6.8)
Alb
2.9 (1.8–3.6)
10.0 (−2–22) 24 (3–123) sCr
1.25 (0.6–4.5)
GFR-EPI
57.15 (18.5–125.1)
PtU
1.4 (0.1–6.8)
Serum Alb
3.5 (2.2–5.7)
Legend: Data at delivery: data observed at the last control before delivery (usually at hospitalization
PtU 24 hour proteinuria, sCr serum creatinine, GFR glomerular filtration rate, Alb serum albumin, na non available
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Table 4 Maternal data at delivery: “controls”: 42 singleton deliveries
Case sCr mg/dL (EPI-GFR mL/min) Stage CKD PtU g/24 h Pt/Alb (g/dL) Weight gain (Kg) sCr mg/dL
(EPI-GFR mL/min) 3 months
PtU g/die
Serum Alb g/dl
3 months
1 0.9 (85) 2 1.5 5.3/2.9 10 0.9 (85) 1.7/3.7
2 0.8 (96) 1 7.2 6.9/3.3 10 0.8 (96) 0.8/4
3 0.7 (113) 1 8.8 6.3/3.1 10 0.8 (96) 0.4/3.8
4 0.8 (94) 1 1.5 na na na na
5 0.9 (86) 2 1.1 5.7/2.9 15 1 (76) 1.3/ 3.7
6 0.5 (136) 1 0.8 5.9/2.9 14 0.5 (129) 0.4/4.3
7 0.5 (124) 1 4.0 5.4/2.5 14 0.5 (125) 1.4/3.2
8 0.5 (141) 1 3.7 5.7/ 3.0 10 0.6 (130) 3.1/4.3
9 1.0 (72) 2 6.2 5.1/2.8 18 1.1 (64) 3.5/ 3.7
10 1.3 (51) 3 7.9 4.7/2 12 1.3 (51) 1.3/ 3.1
11 2.3 (27) 4 8.3 na na na na
12 1.4 (47) 3 2.5 6/3.3 14 1.5 (43) 2.1/na
13 1.4 (50) 3 6.3 5.2/3.1 13 1.4 (49) 1/4.1
14 1.4 (48) 3 3.6 6.4/3.0 18 1.5 (44) 3.2/na
15 1.8 (35) 3 4.4 5.6/2.8 11 1.9 (33) 5.7/3.3
16 1.6 (42) 3 1.8 6.1/3.0 8 1.3 (55) 2.4/3.9
17 1.7 (38) 3 5.6 5.9/2.9 9 1.8 (35) 5.7/3.6
18 1.7 (42) 3 5.6 6.2/3.3 7 1.9 (36) 8/4
19 1.4 (50) 3 6.2 5.3/3.3 8 0.9 (131) 1.6/4.1
20 2.0 (32) 3 5.1 5.7/3.2 4 1.8 (37) 5.4/3
21 2.3 (27.8) 4 7.1 6.8/3.1 10 2.4 (26) 2.7/4.2
22 0.5 (127) 1 0.5 7.5/3.8 17 0.7 (114) 0.8/4.6
Summary data (Cagliari) sCr
1.35 (0.5–2.3)
GFR-EPI
50.5 (27.0–141.0)
3 (1–4) 4.75 (0.5–8.8) Pt
5.8 (4.7–7.5)
Alb
3.0 (2.0–3.8)
10.5 (4–18) sCr
1.20 (0.5–2.4)
GFR-EPI
59.5 (26.0–131.0)
PtU
1.90 (0.4–8.0)
Serum Alb
3.85 (3.0–4.6)
1 0.83 (121) 1 1.08 6.1/3.8 8 1.2 (57) 1.0/3.5
2 0.69 (80.5) 2 1.61 6.1/2.9 12 1.4 (66) 0.9/3.7
3 1.06 (86) 2 2.83 6.343.3 10 1.7 (39) 1.2/ns
4 0.59 (112) 1 0.1 7.01/3.58 8 1.9 (42) 2.5/3.2
5 0.83 (121) 1 1.08 6.08/3.80 8 1.2 (52) 0.8/3.7
6 0.69 (80.5) 2 1.61 6.11/2.95 10 Na na
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Table 4 Maternal data at delivery: “controls”: 42 singleton deliveries (Continued)
7 1.06 (86) 2 2.83 6.34/3.28 2 5.2 (11) na
8 0.59 (112) 1 0.1 7.01/3.58 6 2.1 (29) 0.5/4.0
9 0.83 (121) 1 1.08 6.08/3.80 11 2.2 (29) 1.2/3.7
10 0.69 (80.5) 2 1.61 6.11/2.95 19 1.3 (57) 0.7/4.1
11 1.06 (86) 2 2.83 6.34/3.28 11 1.1 (62) 0.1/4.1
12 0.59 (112) 1 0.1 7.01/3.58 15 1.5 (45) 0.2/3.7
13 0.83 (121) 1 1.08 6.08/3.8 14 0.9 (85) 0.3/3.8
14 0.69 (80.5) 2 1.61 6.11/2.95 7 1.2 (72) na
15 1.06 (86) 2 2.83 6.34/3.28 3 na na
16 0.59 (112) 1 0.1 7.01/3.58 13 0.9 (55a) 0.1/4.2
17 0.83 (121) 1 1.08 6.08/3.80 14 na na
18 0.69 (80.5) 2 1.61 6.11/2.95 3 na na
19 1.06 (86) 2 2.83 6.34/3.28 2 na na
20 0.59 (112) 1 0.1 7.01/3.58 19 na na
Summary data
Torino
sCr
0.76 (0.59–1,06)
GFR-EPI
99.0 (80.5–121.0)
1.34 (0.1–2.83) Pt
6.2 (6.08–7.01)
Alb
3.44 (2.9–3.8)
10.0 (2–19) sCr
1.35 (0.9–5.2)
GFR-EPI
53.5 (11.0–85.0)
PtU
0.75 (0.1–2.5)
Serum Alb
3.7 (3.2–4.2)
Summary data, all sCr
0.83 (0.5–2.3)
GFR-EPI
86.0 (27.0–141.0)
2.15 (0.1–8.8) Pt
6.1 (4.7–7.5)
Alb
3.24 (2.0–3.8)
10.0 (2–19) sCr
1.3 (0.5–5.2)
GFR-EPI
55.0 (11.0–131.0)
PtU
1.25 (0.1–8.0)
Serum Alb
3.8 (3.0–4.6)
P controls vs on diet sCr
0.018
GFR-EPI
0.018
0.390
(Chi2)
0.876 0.010 0.364 sCr
0.565
GFR-EPI
0.813
PtU
0.499
Serum Alb
0.074
Legend: Data at delivery: data observed at the last control before delivery (usually at hospitalization
PtU 24 hour proteinuria, sCr serum creatinine, GFR glomerular filtration rate, Alb serum albumin, na non available
acreatinine clearance (small size)
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Fig. 1 Performance of serum creatinine in on diet patients and controls
Fig. 2 Performance of GFR in on diet patients and controls
Attini et al. BMC Nephrology  (2016) 17:132 Page 14 of 23
Low protein diets are a well-known tool for contrasting
absolute or relative hyperfiltration in the case of nephrotic
syndrome or diabetes, and in the remnant nephrons in
CKD patients [14–16, 39–41]. Pregnancy is another well-
acknowledged condition of physiological hyperfiltration,
which may exert a negative effect on kidney function or
increase proteinuria in CKD patients [42–47].
Control of hyperfiltration and of proteinuria were the
potential advantages we hoped to achieve by a low-
protein diet in pregnancy, when this experience started,
at a time when pregnancy in CKD was often discouraged
and the common practice was to increase protein intake
in pregnancy [48].
Almost unexpectedly, the finding of equivalent or bet-
ter foetal growth in on-diet patients shifted our attention
from the maternal kidneys to the maternal-foetal
exchanges, suggesting a potential effect on the utero-
placental axis [4]. While the low numbers, and the lack
of a homogeneous control group limited the interest in
our findings, this larger cohort with a well-matched
larger control group may allow us to refine the previous
results.
Similarly to our previous studies, in the present series
there is a trend towards better preserved foetal growth,
that reaches statistical significance for the combined out-
come of extremely preterm delivery and small for gesta-
tional age baby (below the 10th centile) (Tables 5 and 6).
Preterm delivery was over 70 % in cases and controls,
witnessing the relevance of the renal impairment; such
prevalence is in line with available studies on patients
with advanced CKD [3, 5, 49–51].
In our analysis the differences between cases and con-
trols regard the “harder” and partially overlapping out-
comes, which include early preterm delivery, small for
gestational age (SGA) and extreme preterm babies, “very
small” babies (birth-weight is at or below1,500 g). The
lower incidence of SGA has to be contextualised with
the similar incidence of early preterm delivery (32.3 % vs
35.7 % in controls), since SGA is a reason for anticipat-
ing delivery [52]. This reinforces our previous findings,
of a better foetal growth in children of on-diet CKD
mothers (Figs. 1 and 2, Tables 5 and 6).
Our study has several limitations, which are partly
shared by other studies on pregnancy: first of all, it is
not randomised. However, randomization of the diet is
hardly feasible outside of pregnancy and may be ethically
unsound in pregnancy.
Secondly, we deal with a small number of patients,
even if ours is the only study to date dedicated to this
issue in CKD pregnancies.
Further research, involving a greater number of sub-
jects is needed to highlight the differences suggested by
our studies and to analyse placental vascularization and
development, thus possibly offering insights into the
pathogenesis of adverse pregnancy-related outcomes in
CKD mothers. Theoretically, a positive effect could be
due to a decrease in “vaso-toxic” elements or to an
increase in “vaso-protective” ones; both are present in
Fig. 3 Performance of proteinuria in on diet patients and controls
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Table 5 Main Maternal-foetal outcomes and intrauterine growth: “on-diet”: 31 singleton deliveries and 3 twin deliveries
Case Gestational age
Weeks (days)
Type of
delivery
Sex of the
baby
Weight (g) Centile (Parazzini) Centile (INeS) Apgar
(1–5 min)
NICU
1 31 + 0 (217) Vaginal M 1595 50–90 55 7–8 Yes
2 33 + 3 (234) CS F 1980 50–90 63 9–9 Yes
3 35 + 2 (247) CS F 1685 <5 5 8–9 Yes
4 31 + 0 (217) CS M 1970 50–90 92 8–8 Yes
5 32 + 6 (230) CS M 2080 50–90 75 9–9 No
6 34 + 1 (239) CS F 1410 <5 3 8–8 Yes
7 28 + 1 (197) CS F 935 10–50 42 7–8 Yes
8 37 + 1 (260) Vaginal M 2620 10–50 16 9–9 No
9 34 + 5 (243) CS M 2180 10-50 37 8–9 No
10 34 + 3 (241) CS F 1710 10–50 13 9–9 Yes
11 33 + 0 (231) CS F 2115 50–90 76 7–8 Yes
12 36 + 3 (255) CS F 2250 10–50 17 9–9 No
13 36 + 6 (258) CS F 2340 10–50 10 9–9 No
14 32 + 2 (226) CS F 1920 50–90 79 6–8 Yes
15 32 + 0 (224) CS F 1550 10–50 31 8–8 Yes
16 34 + 1 (239) Vaginal F 2350 50–90 93 7–8 Yes
17 37 + 4 (263) Vaginal F 2820 10–50 29 9–9 No
18 31 + 6 (223) CS M 1365 10–50 19 8–8 Yes
19 38 + 3 (269) Vaginal F 3180 50–90 62 9–9 No
20 35 + 5 (250) CS M 1790 <5 2 9–9 Yes
21 36 + 1 (253) Vaginal F 2140 5–10 11 9–9 No
22 38 + 6 (272) Vaginal F 2760 10–50 12 9–9 No
23 38 + 5 (271) Vaginal F 3000 10–50 29 9–9 No
24 36 + 6 (258) Vaginal F 2600 10–50 29 8–8 No
25 36 + 5 (257) Vaginal F 2740 10–50 44 9–9 No
26 37 + 2 (261) Vaginal M 2580 10–50 18 8–9 No
27 31 + 6 (223) CS F 1670 10–50 56 8–8 Yes
28 37 + 1 (260) Vaginal M 3070 10–50 55 9–9 No
29 36 + 6 (258) Vaginal F 2830 10–50 50 9–9 No
30 36 + 1 (253) Vaginal F 2250 10–50 22 9–9 No
31 35 + 6 (251) CS F 2020 10–50 23 9/9 No
32 (twin) 31 + 4 (221) CS aM 1270 5–10 16 4–7 Yes
F 1275 10–50 22 7–8 Yes
33 (twin) 36 + 4 (256) CS F 2350 10–50 16 9–9 No
M 2400 10–50 12 8–9 No
34 (twin) 35 + 6 (251) CS M 2920 50–90 72 8/9 No
M 3040 50–90 81 8/9 No
Summary data:
singletons
Below 37w: 24
(77.4 %)
Below 34w: 10
(32.3 %)
Below 28: 0
Median 35
(28–38)
CS
17
(54.8 %)
M
9 (29.0 %)
Below 1500 g: 3
(9.7 %)
Below 2500 g: 21
(67.7 %)
Median 2140
(935–3180)
Below 5th: 3/31
(9.7 %)
Below 5th: 2/31
(6.5 %)
5 min:
9 (6–9)
10 min
9 (8–9)
Yes
14
(45.2 %)
Vaginal
14
(45.2 %)
F
22
(71.0 %)
Below 10th
4/31 (12.9 %)
Below 10th 3/31
(9.7 %)
median
29 (2–93)
No
17
(54.8 %)
Legend: aNeonatal death, CS caesarean section, NICU neonatal Intensive Care Unit, M male, F female, Parazzini Parazzini growth charts, INeS Italian Neonatal Study
growth charts
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Table 6 Main Maternal-foetal outcomes, and intrauterine growth: “controls”: 42 singleton deliveries
Case Gestational age Type of
delivery
Sex of the
baby
Weight (g) Centile (Parazzini) Centile (INeS) Apgar (1–
5 min)
NICU
1 32 + 5 CS M 1470 10–50 15 6–7 Yes
2 31 + 6 CS F 1500 10–50 41 7–9 Yes
3 27 + 3 CS Fa 700 / 16 7–7 Yes
4 29 + 3 CS M 610 <5 1 4–8 Yes
5 40 + 3 CS F 2750 10–50 7 8–10 No
6 36 + 2 CS M 3230 50–90 86 5–7 Yes
7 37 + 1 CS M 2340 <5 8 9–10 No
8 33 + 0 CS F 1950 10–50 59 8–9 Yes
9 37 + 0 CS M 2300 <5 5 9–10 No
10 33 + 5 CS M 1900 10–50 34 9–9 Yes
11 32 + 1 CS M 2180 50–90 93 na Yes
12 37 + 4 CS M 2870 10–50 27 10–10 No
13 36 + 4 CS F 2630 10–50 37 9–10 No
14 36 + 3 CS M 2650 10–50 32 8–9 Yes
15 35 + 4 CS F 2400 10–50 48 10–10 No
16 37 + 1 CS M 2970 10–50 45 8–10 No
17 32 + 0 CS M 1950 50–90 81 8–8 Yes
18 34 + 6 CS M 2330 10–50 49 8–10 No
19 28 + 4 CS F 820 10–50 17 7–9 Yes
20 25 + 2 CS Ma 500 / 7 3–5 Yes
21 35 + 4 vaginal F 2450 10–50 58 8–9 No
22 36 + 0 vaginal F 2600 5–10 13 9–10 No
Summary data:
Cagliari
Below 37w: 17 (77.3 %)
Below 34w: 10 (45.5 %)
Below 28w: 2 (9.1 %)
median
34.5 (25–40)
CS
20 (90.9 %)
M
13 (59.1 %)
Below 1500 g:
5 (22.7 %)
Below 2500 g:
15 (68.2 %)
Below 5th or below 28 w: 5/22
(22.7 %)
Below 5th: 1/22 (4.5 %) 5 min:
8 (3–10)
10 min
9 (5–10)
Yes
12
(54.4 %)
Vaginal
2 (9.1 %)
F
9 (40.9 %)
Below 10th or below 28 w: 6/22
(27.3 %)
Below 10th: 5/22
(22.7 %)
median
33 (1–93)
No
10
(45.5 %)
1 37 + 0 CS F 3330 50–90 92 9–9 No
2 31 + 0 CS M 1100 5–10 10 9–9 Yes
3 33 + 0 CS M 1425 5–10 9 7–9 Yes
4 36 + 5 Vaginal F 2410 10–50 24 9–9 No
5 36 + 2 Vaginal F 2160 5–10 14 9–9 No
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Table 6 Main Maternal-foetal outcomes, and intrauterine growth: “controls”: 42 singleton deliveries (Continued)
6 36 + 5 Vaginal F 2600 10–50 40 9–9 No
7 28 + 2 CS M 750 5–10 9 5–8 Yes
8 36 + 2 CS M 2500 10–50 30 9–9 No
9 32 + 5 CS M 1300 5–10 5 9–9 Yes
10 38 + 0 Vaginal M 2280 <5 2 8–8 No
11 34 + 2 Vaginal F 2160 10–50 39 8–9 No
12 38 + 3 Vaginal F 3170 50–90 61 9–9 No
13 37 + 6 Vaginal F 3050 50–90 59 8–8 No
14 38 + 0 CS M 2565 5–10 6 9–9 No
15 32 + 2 CS M 1440 10–50 19 7–9 Yes
16 38 + 4 Vaginal M 2850 10–50 18 7–8 No
17 35 + 6 Vaginal F 2900 50–90 85 9–9 No
18 35 + 4 CS M 1620 <5 1 9–9 Yes
19 36 + 6 CS F 2510 10–50 29 9–9 No
20 37 + 6 CS M 3180 50–90 59 9–9 No
Summary data:
Torino
Below 37 w: 13 (65.0 %)
Below 34 w: 5 (25.0 %)
Below 28 w: 0 median
36 (28–38)
CS
11 (55.0 %)
M
11 (55.0 %)
Below 1500 g: 5 (25.0 %)
Below 2500 g: 10
(50.0 %)
median
2455
(750–3330)
Below 5th: 2/20
(10.0 %)
Below 5th: 2/20
(10.0 %)
5 min: 8 (5–9)
10 min: 9
(8–9)
Yes
6
(30.0 %)
Vaginal
9 (45.0 %)
F
9 (45.0 %)
Below 10th 8/20
(40.0 %)
Below 10th: 6/20
(30.0 %)
median
21.5 (1–92)
No
14
(70.0 %)
Summary data: all Below 37 w: 30 (71.4 %)
Below 34 w: 15 (35.7 %)
Below 28 w: 2 (4.8 %)
median
35.5 (25–40)
CS
31 (73.8 %)
M
24 (57.1 %)
Below 1500 g: 10
(23.8 %)
Below 2500 g: 25
(59.5 %)
median
2335
(500–3330)
Below 5th:
7/42 (16.7 %)
Below 10th: 14/42 (33.3 %)
Below 5th: 3/42 (7.1 %)
Below 10th: 11/42
(26.2 %)
median
28.0 (1–93)
5 min: 8 (5–9)
10 min: 9
(8–9)
Yes
18/42
(42.9 %)
P
diet vs controls
Median: 0.839
(Mann–Whitney) Below 37:
0.759
(Chi2 Yates)
Below 34: 0.954 (Chi2 Yates)
Below 28: 0.505 (Fisher)
0.150
Chi2
(Yates)
0.032
Chi2
(Yates)
0.742
Mann–Whitney
Below 1500 g: 0.104
(Fisher)
Below 2500 g: 0.319
(Fisher)
Below 5th:
0.308 (Fisher)
Below 10th:
0.040 (Fisher)
Below 5th: 0.643
(Fisher)
Below 10th:
0.068 (Fisher)
5 min: 0.501
10 min: 0.076
(Mann–
Whitney)
1.000
Chi2
(Yates)
Legend: aNeonatal death, CS caesarean section, NICU neonatal Intensive Care Unit, M male, F female, Parazzini Parazzini growth charts, INeS Italian Neonatal Study growth charts. Fisher: one tailed test
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Fig. 5 Relationship between birth-weight and prematurity in on diet patients and controls: males
Fig. 4 Relationship between birth-weight and prematurity in on diet patients and controls: females
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the study diet. A growing amount of data suggests that
red meat consumption is associated with an increase in
cardiovascular risk, while diets that are rich in vegeta-
bles, legumes and grains (especially those with a low gly-
caemic index) may be protective against endothelial
dysfunction [53–63].
The specific advantage of vegetable proteins and of
supplementation with ketoacids may have played an im-
portant role, as it has been suggested in experimental
models, which show a protective endothelial effect of
ketoacids in rats with kidney disease and a decrease in
the risk of CKD in the offspring of rats with genetic
kidney diseases that are fed a soya rich diet [64, 65].
In the absence of a randomised controlled trial that could
present ethical limitations in pregnancy, we hope that our
data may stimulate new research on this important issue.
Conclusion
Vegan-vegetarian diets with moderate protein restric-
tion, supplemented with amino and keto-acids, are safe
in pregnancy and may be followed without appreciable
side effects. A favourable trend towards improving foetal
outcomes was observed for growth and timing of deliv-
ery, and reached statistical significance for the combined
outcome of small for gestational age babies and ex-
tremely preterm delivery, which are also the most robust
predictors of future health.
While waiting for further studies to highlight the
underlying mechanisms, we hope that this positive find-
ing may raise awareness to the important issue of diet,
CKD and pregnancy.
Appendix
A “vegan/ vegetarian” diet for pregnant women with CKD
(moderate protein restriction, supplemented with alpha-
keto analogues)
This diet is based on some very simple assumptions:
– first point: a low-protein diet is associated with a
reduction of the functional “work-load” for the dis-
eased kidneys; this is important since pregnancy in-
creases the “work-load” of the kidneys, which may
increase proteinuria and thus reduce kidney func-
tion in the long term.
– second point: proteins of vegetable origin cause a
lesser “workload” for the kidney as compared to
animal-derived proteins, and therefore a “vegan-
vegetarian” diet is better suited to stabilize renal
function in pregnant women with chronic kidney
disease.
– third point: vegan (no animal or animal-derived
food of any kind) and vegetarian (no food from a
living source: milk and derivate are allowed) diets
are safe in pregnancy (regardless of the presence of
CKD), if well balanced and controlled for protein
deficits.
– fourth point: the diet should allow a good quality
of life and has to be followed with flexibility,
adapting to the preferences of the individual. In
pregnancy, we need to pay more attention to
maintaining an adequate level of several nutrients,
including many vitamins and minerals (the most
important ones that we know are: vitamin B12, folic
acid, vitamin D, calcium), and to not gaining too
much weight (this is why we ask you to pay
attention not only to the quality of the food, but
also to the quantity).
– fifth point: proteins are contained in “animal-
derived” food (meat, fish, eggs, poultry and dairy
products) and in plant- derived food (grains,
cereals, legumes, soya, etc). While some animals
(cows for example) are able to build up all the
aminoacids from “energy” (i.e., grass), humans are
not. Therefore, “animal-derived” proteins are called
“noble” or “complete”, since they contain ALL the
protein components (amino-acids) that we need;
plant- derived” proteins are called “incomplete” or
“non noble” since their proteins do not contain
ALL the aminoacids we need. Every plant-derived
protein contains some of them, but we need to put
together several different types of plant- derived
food to complete them.
– sixth point: the use of “supplements” (called alpha-
kappa or ketosteril that are a mixture of essential
aminoacids), allows “completion” of the vegetable
proteins, avoiding the risk of nutritional deficits
even in patients who do not have time (or like to)
combine different “plant-derived” foods.
Important: There are very few studies in the medical
literature on low-protein diets in pregnant CKD patients
and our experience, obtained in a limited number of
patients, is one of the few available ones. To date, the re-
sults have been highly positive, also thanks to the close
collaboration among us (nephrologists, obstetricians, di-
eticians) and to the good compliance of the patients that
previously followed the diet. Therefore, please report
any doubts or side effects immediately to help us follow
you better and better understand what we can do to
improve our approach.
In short:
You can eat anything that grows on the earth, under
the earth and on trees, and anything that is derived from
what grows over and under the earth and on the trees
(plants). The only limit is your weight: be careful with
fruit it is rich in sugars, and sugar is allowed “with mod-
eration” in pregnancy (PS: olive oil is derived from trees,
but has no sugar: it can be used freely).
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You should not eat anything that walks on earth, flies
in the air or swims in the water or that is derived from
animals, with the exception of butter that contain mainly
fat, and should be limited (not too much fat in
pregnancy).
However, in the “free” meals you can eat ANYTHING
YOU WANT (quality) but NOT TOO MUCH (quantity)
to avoid gaining too much weight.
Supplements are prescribed as one tablet every 8–10 kg
of body weight per day, sub-divided over the main meals.
The tablets can be taken “in the middle of the meal”, at
the beginning, or at the end of the meal. The number of
pills may increase (or decrease) in pregnancy depending
on your condition and biochemical test results.
Supplements are not required in the “free” meals.
In detail
Breakfast
For breakfast you can have: tea, coffee, soy drink or
soy yoghurt, with bread or biscuits with jam, cereal
(such as corn or oat flakes or muesli), or a slice of home
made cake (butter, oil, yolk, and a small quantities of
milk or yoghurt are allowed) (if you cannot do without,
you are allowed to have milk for breakfast…).
Alternatively, for those who prefer a savoury breakfast,
you can have bread with olive oil and tomatoes or olives,
bread and tofu, crackers or bread sticks with extra virgin
olive oil.
1–2 (specify) ____ tablets of alpha-kappa
Lunch and dinner (for each meal), please combine
the following
– Pasta or rice or couscous or cereals (like barley,
millet, kamut, wheat) seasoned as follows (olive oil
is always the best)
– Legumes (for example, chickpeas, peas, beans,
lentils, etc)
– Vegetables of any kind (raw or cooked)
(see indications for toxoplasmosis)
– Bread or bread sticks or crackers with extra virgin
olive oil
– Fresh fruit (indicatively 150–200 g).
2–3 (specify) ____ tablets of alpha-keto analogue
Potatoes can replace bread or pasta.
Legumes should be consumed at least in one main
meal in association with pasta, rice or other cereals. If
you like, you can use tofu, tempeh or seitan instead of
legumes.
Oily nuts such as walnuts (4–6 per day) are useful for
their high content of “good” fat (that, like olive oil, pro-
tects from atherosclerosis and may help protect the pla-
cental vessels).
Snacks
Snacks (mid-morning, mid-afternoon) are welcome:
– 1 cup of soy yoghurt or soy drink
– Bread or biscuits or crackers or bread sticks made
with extra virgin olive oil
– Bread with tofu, olives and olive paste, tomato,
vegetables
– 1 cup of plain yoghurt or fruit salad
– 1 piece of fresh fruit
– raw vegetables like fennel, celery, peppers,
cucumbers, tomatoes, carrots may be used if you
are not receptive for toxoplasmosis (please WASH
VERY WELL in any case).
– (regular yoghurt may be an alternative, at least
occasionally)
Dressings/cooking
Cook as you prefer (stewed, steamed, grilled, broiled,
baked, fried with extra virgin olive oil).
Use extra virgin olive oil for seasoning and avoid
mixed seed oil, butter, lard, margarine, cream, sauces
(such as mayonnaise, ketchup, tuna sauce, etc.), and
items containing sodium glutamate (not good for your
vessels or for the placental vessels). Also avoid: vegetable
fat, non hydrogenated vegetable fats, palm oil or coconut
oil (similar reasons).
Natural spices, herbs (such as rosemary, sage, basil,
oregano, thyme, parsley), chili, onion, garlic, lemon juice,
vinegar, balsamic vinegar, miso, tamari, shoyu, can be
used; however, in case of tamari or miso, please check
that they do not have added ingredients.
Use iodized salt, which should not be confused with
“sea salt” or “whole salt”. Iodized salt is common salt to
which iodine has been added (good for thyroid func-
tion). In order to increase the intake of some useful min-
erals (calcium, iron, potassium …) sesame seeds,
sunflower seeds and pumpkin seeds may be added (for
example 1 tablespoon).
With regard to baked goods, (crackers, bread sticks),
those without added fat or made with extra virgin olive
oil, sunflower or corn oil should be preferred.
Drinks and sweets
Drink water (still or sparkling) throughout the day.
Check with your nephrologist to establish the amount.
Drink wine and beer only occasionally and in small
quantities during pregnancy. Cocktails, spirits and
liqueurs are forbidden. Due to the high sugar content,
avoid soft drinks, syrups, juices, fruit juices and soluble
herbal tea.
Reduce your intake of foods with high sugar con-
tent: brown sugar, ice-cream, honey, malt, fruit jel-
lies, croissants, cakes, cream, chocolate, cookies,
candy, etc.. Avoid artificial sweeteners like aspartame
(E951), acesulfame K (E950), saccharin (E954) and
sucralose (E955), cyclamate (E952), neohesperidine
DC (E959).
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Toxoplasmosis and listeriosis
(Two infections that may be transmitted by food). If
you are receptive to toxoplasmosis, eat only well-cooked
vegetables and meat (during the free meals). CAUTION
with STRAWBERRIES, berries, mushrooms, fresh herbs
(like parsley, basil, sage …). In case of doubt, freeze the
item to eliminate Toxoplasma. To prevent listeriosis,
avoid vacuum-packed products (such as smoked sal-
mon), raw milk, and unpasteurized cheese (such as gor-
gonzola, taleggio). Check the details with your dietician.
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